Compare Ascendis Pharma A/S (ASND) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Invesco DB Agriculture Fund — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Invesco DB Agriculture Fund trades at $27.66. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| ASND | DBA | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $28.73 |
52-Week Low | $163.32 | $25.44 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DBA (Invesco DB Agriculture Fund) trades at $27.77, up 0.22% today, with a bullish technical signal supported by moving averages but tempered by overbought oscillators. The ETF tracks agricultural commodities including corn, soybeans, wheat, and livestock, benefiting from recent supply disruptions and strong commodity price trends. Recent news highlights weather impacts on Brazilian coffee harvests and China's $17 billion U.S. crop purchase commitment through 2028.
The agricultural commodity exposure positions DBA for potential gains amid global supply constraints, though high RSI levels suggest near-term consolidation risk. Key support sits at $27 with resistance at $28-29. Investors should monitor crop reports and geopolitical developments affecting commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
